CMD22 Capital Markets Day

Commercial execution / Innovation and therapeutic focus Closing remarks NASH and Alzheimer's disease impact millions of people globally Too often the diseases go undiagnosed and have no or limited treatment options Semaglutide is investigated in specific patient populations for treatment of NASH F2-F3 and MCI and mild dementia due to Alzheimer's disease novo nordisk NADIA SADI Nadia lives with NASH Denmark

View entire presentation